1. Home
  2. CMPX vs EARN Comparison

CMPX vs EARN Comparison

Compare CMPX & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMPX
  • EARN
  • Stock Information
  • Founded
  • CMPX 2014
  • EARN 2012
  • Country
  • CMPX United States
  • EARN United States
  • Employees
  • CMPX N/A
  • EARN N/A
  • Industry
  • CMPX Biotechnology: Pharmaceutical Preparations
  • EARN Real Estate Investment Trusts
  • Sector
  • CMPX Health Care
  • EARN Real Estate
  • Exchange
  • CMPX Nasdaq
  • EARN Nasdaq
  • Market Cap
  • CMPX 291.8M
  • EARN 187.6M
  • IPO Year
  • CMPX N/A
  • EARN 2013
  • Fundamental
  • Price
  • CMPX $2.78
  • EARN $5.80
  • Analyst Decision
  • CMPX Strong Buy
  • EARN Buy
  • Analyst Count
  • CMPX 9
  • EARN 2
  • Target Price
  • CMPX $12.67
  • EARN $6.00
  • AVG Volume (30 Days)
  • CMPX 929.9K
  • EARN 243.8K
  • Earning Date
  • CMPX 08-11-2025
  • EARN 08-11-2025
  • Dividend Yield
  • CMPX N/A
  • EARN 16.67%
  • EPS Growth
  • CMPX N/A
  • EARN N/A
  • EPS
  • CMPX N/A
  • EARN N/A
  • Revenue
  • CMPX $850,000.00
  • EARN $35,893,000.00
  • Revenue This Year
  • CMPX N/A
  • EARN $3.21
  • Revenue Next Year
  • CMPX N/A
  • EARN $18.63
  • P/E Ratio
  • CMPX N/A
  • EARN N/A
  • Revenue Growth
  • CMPX N/A
  • EARN 43.30
  • 52 Week Low
  • CMPX $0.77
  • EARN $4.33
  • 52 Week High
  • CMPX $4.08
  • EARN $7.20
  • Technical
  • Relative Strength Index (RSI)
  • CMPX 68.90
  • EARN 55.89
  • Support Level
  • CMPX $2.50
  • EARN $5.68
  • Resistance Level
  • CMPX $2.71
  • EARN $5.79
  • Average True Range (ATR)
  • CMPX 0.19
  • EARN 0.07
  • MACD
  • CMPX 0.01
  • EARN -0.01
  • Stochastic Oscillator
  • CMPX 87.14
  • EARN 71.43

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.

Share on Social Networks: